樂普生物－Ｂ(02157.HK)公布，其候選藥物MRG004A (一種新型靶向組織因子的特異性抗體藥物偶聯物)，已獲美國食品藥品監督管理局(FDA)授予快速通道資格(FTD)，用於治療胰腺癌。
MRG004A是一種新型靶向組織因子的特異性抗體藥物偶聯物，目前在美國及中國進行I/II期臨床研究。公司已觀察到胰腺癌、三陰性乳腺癌及宮頸癌的抗腫瘤活性信號。
- Headlines
- 樂普生物－Ｂ(02157.HK)治療胰腺癌候選藥物獲美國授予快速通道資格
樂普生物－Ｂ(02157.HK)治療胰腺癌候選藥物獲美國授予快速通道資格
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Hot News
Updated
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.